Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial

The Lancet HIV

Volumn 4, Issue 4, 2017, Pages e154-e160

  Sax, Paul E ^a   DeJesus, Edwin ^b   Crofoot, Gordon ^c   Ward, Douglas ^d   Benson, Paul ^e   Dretler, Robin ^f   Mills, Anthony ^g   Brinson, Cynthia ^h   Peloquin, Julie ⁱ   Wei, Xuelian ⁱ   White, Kirsten ⁱ   Cheng, Andrew ⁱ   Martin, Hal ⁱ   Quirk, Erin ⁱ  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c Gordon Crofoot Research   (United States)

^d DUPONT COMPANY   (United States)

^e Be Well Medical   (United States)

^f Atlanta Infectious Diseases Group Professional Corporation   (United States)

^g Southern California s Men s Medical Group Men s Health Foundation   (United States)

^h Central Texas Clinical Research   (United States)

ⁱ GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BICTEGRAVIR; CREATINE KINASE; DOLUTEGRAVIR; EMTRICITABINE PLUS TENOFOVIR ALAFENAMIDE; PLACEBO; VIRUS RNA; ADENINE; EMTRICITABINE; FUSED HETEROCYCLIC RINGS; GS-7340;

ADULT; ALCOHOL ABUSE; ARTHRALGIA; ARTICLE; BACKACHE; CD4 LYMPHOCYTE COUNT; CHLAMYDIASIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLATULENCE; FURUNCULOSIS; GASTROENTERITIS; GENETIC RESISTANCE; GENOTYPE; HEADACHE; HEMORRHOID; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TIETZE SYNDROME; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VIREMIA; VIRUS LOAD; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHASE 2 CLINICAL TRIAL; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EMTRICITABINE; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 85012877727     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(17)30016-4     Document Type: Article

References (24)

1. 1 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2016, Department of Health and Human Services, Washington, DC.
2. 2 Günthard, HF, Saag, MS, Benson, CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA Panel. JAMA 316 (2016), 191–210.
3. 3 European AIDS Clinical Society. Guidelines. Version 8.0. October 2015, 2015, European AIDS Clinical Society, Brussels.
4. 4 Lennox, JL, Landovitz, RJ, Ribaudo, HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 161 (2014), 461–471.
5. 5 Walmsley, SL, Antela, A, Clumeck, N, Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 Infection. N Engl J Med 369 (2013), 1807–1818.
6. 6 Clotet, B, Feinberg, J, van Lunzen, J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 383 (2014), 2222–2231.
7. 7 Squires, K, Kityo, C, Hodder, S, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV 3 (2016), e410–e420.
8. 8 Orell C, Hagins D, Belonosova E, et al. Superior efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) compared with ritonavir (RTV) boosted atazanavir (ATV) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA Study). International AIDS Conference; Durban, South Africa; July 18–22, 2016. Abstract 10215.
9. 9 Tsiang, M, Jones, GS, Goldsmith, J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother 60 (2016), 7086–7097.
10. 10 Gallant JE, Thompson M, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. J Acquir Immune Defic Syndr (in press).
11. 11 Cockcroft, DW, Gault, MH, Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976), 31–41.
12. 12 Smith, F, Hammerstorm, T, Soon, G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J 45 (2011), 291–300.
13. 13 D:A:D Study Group, Sabin, CA, Worm, SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371 (2008), 1417–1426.
14. 14 Worm, SW, Sabin, C, Weber, R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 201 (2010), 318–330.
15. 15 Young, J, Xiao, Y, Moodie, EE, et al. Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 69 (2015), 413–421.
16. 16 Friis-Møller, N, Thiébaut, R, Reiss, P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 17 (2010), 491–501.
17. 17 Marcus, JL, Neugebauer, RS, Leyden, WA, et al. Use of abacavir and risk of cardiovascular disease among HIV-infected individuals. J Acquir Immune Defic Syndr 71 (2016), 413–419.
18. 18 Sabin, CA, Reiss, P, Ryom, L, et al., for the D:A:D Study Group. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med, 14, 2016, 61.
19. 19 Ding, A, Andraca-Carrera, E, Cooper, C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 61 (2012), 441–447.
20. 20 Mills, A, Arribas, JR, Andrade-Villanueva, J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 16 (2016), 43–52.
21. 21 Pozniak, A, Arribas, JR, Gathe, J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, phase 3 study. J Acquir Immune Defic Syndr 71 (2016), 530–537.
22. 22 Gallant, JE, Daar, ES, Raffi, F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV 3 (2016), e158–e165.
23. 23 Kulkarni, R, Abram, ME, McColl, DJ, et al. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients. HIV Clin Trials 15 (2014), 218–230.
24. 24 White, KL, Kulkarni, R, McColl, DJ, et al. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients. Antivir Ther 20 (2015), 317–327.